Huntington's disease: a clinical review
- PMID: 21171977
- PMCID: PMC3022767
- DOI: 10.1186/1750-1172-5-40
Huntington's disease: a clinical review
Abstract
Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia. Prevalence in the Caucasian population is estimated at 1/10,000-1/20,000. Mean age at onset of symptoms is 30-50 years. In some cases symptoms start before the age of 20 years with behavior disturbances and learning difficulties at school (Juvenile Huntington's disease; JHD). The classic sign is chorea that gradually spreads to all muscles. All psychomotor processes become severely retarded. Patients experience psychiatric symptoms and cognitive decline. HD is an autosomal dominant inherited disease caused by an elongated CAG repeat (36 repeats or more) on the short arm of chromosome 4p16.3 in the Huntingtine gene. The longer the CAG repeat, the earlier the onset of disease. In cases of JHD the repeat often exceeds 55. Diagnosis is based on clinical symptoms and signs in an individual with a parent with proven HD, and is confirmed by DNA determination. Pre-manifest diagnosis should only be performed by multidisciplinary teams in healthy at-risk adult individuals who want to know whether they carry the mutation or not. Differential diagnoses include other causes of chorea including general internal disorders or iatrogenic disorders. Phenocopies (clinically diagnosed cases of HD without the genetic mutation) are observed. Prenatal diagnosis is possible by chorionic villus sampling or amniocentesis. Preimplantation diagnosis with in vitro fertilization is offered in several countries. There is no cure. Management should be multidisciplinary and is based on treating symptoms with a view to improving quality of life. Chorea is treated with dopamine receptor blocking or depleting agents. Medication and non-medical care for depression and aggressive behavior may be required. The progression of the disease leads to a complete dependency in daily life, which results in patients requiring full-time care, and finally death. The most common cause of death is pneumonia, followed by suicide.
Similar articles
-
Juvenile Huntington's Disease: Diagnostic and Treatment Considerations for the Psychiatrist.Curr Psychiatry Rep. 2017 Feb;19(2):9. doi: 10.1007/s11920-017-0759-9. Curr Psychiatry Rep. 2017. PMID: 28168595 Review.
-
[Huntington's disease with childhood and adolescent onset: course of disease, clinical presentation and diagnostic challenges].Fortschr Neurol Psychiatr. 2020 Oct;88(10):661-667. doi: 10.1055/a-1082-6605. Epub 2020 May 5. Fortschr Neurol Psychiatr. 2020. PMID: 32369858 Review. German.
-
Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients.Arch Neurol. 2007 Jun;64(6):813-9. doi: 10.1001/archneur.64.6.813. Arch Neurol. 2007. PMID: 17562929
-
Huntington Disease.2023 Aug 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32644592 Free Books & Documents.
-
Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.Am J Med Genet B Neuropsychiatr Genet. 2015 Oct;168(7):573-85. doi: 10.1002/ajmg.b.32332. Epub 2015 Jun 16. Am J Med Genet B Neuropsychiatr Genet. 2015. PMID: 26079385 Free PMC article.
Cited by
-
Application of CRISPR/Cas9 System in the Treatment of Alzheimer's Disease and Neurodegenerative Diseases.Mol Neurobiol. 2024 Apr 19. doi: 10.1007/s12035-024-04143-2. Online ahead of print. Mol Neurobiol. 2024. PMID: 38639864 Review.
-
Health state utility estimates for value assessments of novel treatments in Huntington's disease: a systematic literature review.Health Qual Life Outcomes. 2024 Apr 16;22(1):33. doi: 10.1186/s12955-024-02242-1. Health Qual Life Outcomes. 2024. PMID: 38627749 Free PMC article. Review.
-
Postmortem neuropathology in early Huntington disease.J Neuropathol Exp Neurol. 2024 Apr 19;83(5):294-306. doi: 10.1093/jnen/nlae022. J Neuropathol Exp Neurol. 2024. PMID: 38553027 Free PMC article.
-
Large animal models for Huntington's disease research.Zool Res. 2024 Mar 18;45(2):275-283. doi: 10.24272/j.issn.2095-8137.2023.199. Zool Res. 2024. PMID: 38485497 Free PMC article. Review.
-
Optimizing Screening for Intrastriatal Interventions in Huntington's Disease Using Predictive Models.Mov Disord. 2024 May;39(5):855-862. doi: 10.1002/mds.29749. Epub 2024 Mar 11. Mov Disord. 2024. PMID: 38465778
References
-
- Bruyn GW. In: Handbook of Clinical Neurology. Vinken PJ, Bruyn GW, editor. Vol. 6. Elsevier Amsterdam; 1968. Huntington's chorea: historical, clinical and laboratory synopsis; pp. 298–378.
-
- Bates G, Harper P, Jones L. Huntington's disease. 3. Oxford, Oxford University press; 2002.
-
- van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci. 2007;19:441–8. - PubMed
-
- Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, Kayson E, Orme C, Shoulson I. Huntington Study Group. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60:998–1001. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical